Work

Adverse events associated with bimekizumab for moderate-to-severe plaque psoriasis: A retrospective, multicenter, post-hoc analysis

Year: 2025

Type: article

Abstract: Bimekizumab, a monoclonal antibody selectively inhibiting interleukin (IL) 17A and IL-17F, was Food and Drug Administration–approved in 2023 for the treatment of moderate-to-severe plaque psoriasis in adults. Clinical trials have demonstrated a comparable safety profile to other IL-17A antagonists, with a slightly increased risk of fungal infection and the additional warning for suicidal ideation and behavior.1-3 Post-hoc analyses of adverse events (AEs) associated with bimekizumab outside of clinical trials are scarce, with no studies to date published in the United States.

Source: JAAD International

DOI: 10.1016/j.jdin.2025.02.001

Authors: Nikki Zangenah, Maria Vazquez-Machado, Nicole Loranger, Soha Elshaboury, Kimberly Hashemi, Avery H. LaChance

Institutions: Brigham and Women's Hospital, University of Massachusetts Chan Medical School, Mass General Brigham, Medical University of South Carolina

Language: English

Topic: Psoriasis: Treatment and Pathogenesis

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,575